JP2022523704A5 - - Google Patents

Info

Publication number
JP2022523704A5
JP2022523704A5 JP2021543509A JP2021543509A JP2022523704A5 JP 2022523704 A5 JP2022523704 A5 JP 2022523704A5 JP 2021543509 A JP2021543509 A JP 2021543509A JP 2021543509 A JP2021543509 A JP 2021543509A JP 2022523704 A5 JP2022523704 A5 JP 2022523704A5
Authority
JP
Japan
Prior art keywords
acid
pharmaceutical composition
composition according
fatty acid
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/073099 external-priority patent/WO2020151633A1/en
Publication of JP2022523704A publication Critical patent/JP2022523704A/ja
Publication of JP2022523704A5 publication Critical patent/JP2022523704A5/ja
Pending legal-status Critical Current

Links

JP2021543509A 2019-01-25 2020-01-20 医薬組成物 Pending JP2022523704A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/073112 2019-01-25
CN2019073112 2019-01-25
PCT/CN2020/073099 WO2020151633A1 (en) 2019-01-25 2020-01-20 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2022523704A JP2022523704A (ja) 2022-04-26
JP2022523704A5 true JP2022523704A5 (https=) 2023-01-31

Family

ID=71736646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543509A Pending JP2022523704A (ja) 2019-01-25 2020-01-20 医薬組成物

Country Status (5)

Country Link
US (1) US20220193095A9 (https=)
EP (1) EP3914234A4 (https=)
JP (1) JP2022523704A (https=)
CN (1) CN113473974A (https=)
WO (1) WO2020151633A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
CN114762693A (zh) * 2020-12-31 2022-07-19 成都海博为药业有限公司 一种载药量高的阿比特龙药物组合物及其制备方法及用途
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
JP2024512659A (ja) * 2021-04-01 2024-03-19 アール．ピー．シェーラー テクノロジーズ，エルエルシー 医薬製剤におけるアニオン性キレート剤としてのリン脂質
JP2024533332A (ja) * 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2677613B2 (ja) * 1988-06-24 1997-11-17 エーザイ株式会社 ビタミンｅ又はその誘導体の吸収促進組成物
KR20030009416A (ko) * 2000-04-04 2003-01-29 시오노기세이야쿠가부시키가이샤 고지용성 약물을 함유하는 유성 조성물
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20080145411A1 (en) * 2006-10-06 2008-06-19 Kaneka Corporation Composition of high absorbability for oral administration comprising oxidized coenzyme q10
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
EP2682111A1 (en) * 2009-12-31 2014-01-08 Differential Drug Development Associates LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN103169712B (zh) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 提高生物利用度的度他雄胺制剂及其制备方法
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
KR20140043579A (ko) * 2012-09-24 2014-04-10 한국콜마주식회사 무복계면 디클로페낙나트륨 및 그 제조방법
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
SG11201701139YA (en) * 2014-09-18 2017-03-30 Iceutica Inc Abiraterone acetate formulation and methods of use
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone
CN105055314A (zh) * 2015-09-28 2015-11-18 杭州安德科技有限公司 一种阿比特龙的口腔喷雾剂及其使用和制备方法
CA2922959C (en) * 2016-03-03 2018-01-02 Pankaj Modi Orally administrable composition

Similar Documents

Publication Publication Date Title
JP2022523704A5 (https=)
US20250099489A1 (en) Abiraterone prodrugs
US10286077B2 (en) Steroid hormone compositions in medium chain oils
US7138389B2 (en) Oral androgen therapy using modulators of testosterone bioavailability
AU2002244247B2 (en) Use of certain steroids for treatment of blood cell deficiencies
JP2022523704A (ja) 医薬組成物
US20040014734A1 (en) Farnesoid X-activated receptor agonists
US20030083231A1 (en) Blood cell deficiency treatment method
BR112012025961B1 (pt) Composição farmacêutica oral
CA2582231A1 (en) Steroid analogs and uses
JP2010501575A (ja) 癌を治療するための方法及び組成物
CA2768773A1 (en) Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
SE463074B (sv) Anvaendning av aromatashaemmare och antiandrogener foer framstaellning av laekemedel foer profylax och terapi av benign prostatahyperplasi
AU2002244247A1 (en) Use of certain steroids for treatment of blood cell deficiencies
US20140288039A1 (en) Lipobalanced long chain testosterone prodrugs for oral delivery
JP2011503075A5 (https=)
CN111432805B (zh) 3α-乙炔基-3β-羟基雄甾烷-17-酮肟的药物制剂
JP2025504430A5 (https=)
JP4519640B2 (ja) 非ペプチドレニン阻害薬及び界面活性剤を含有する医薬製剤
KR102238478B1 (ko) 구강 전달용 지방균형잡힌 장쇄 테스토스테론 에스테르
JP2002539135A5 (https=)
JP2003160496A (ja) グリチルリチン経口投与剤
HK40130201A (zh) 阿比特龙前药
HK40065545B (zh) 阿比特龙前药
JPH09511251A (ja) ステロイド性５−アルファ−レダクターゼ阻害剤での心臓血管系疾患の治療